

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

ORC

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 38/09, 47/34	AI	(11) International Publication Number: WO 00/32218 (43) International Publication Date: 8 June 2000 (08.06.00)
(21) International Application Number: PCT/GB99/04045 (22) International Filing Date: 2 December 1999 (02.12.99) (30) Priority Data: 9826662.0 3 December 1998 (03.12.98) GB (71) Applicant (for all designated States except US): FERRING BV (NL/NL); Polaris Avenue 144, NL-2132 JX Hoofddorp (NL). (72) Inventors; and (75) Inventors/Applicants (for US only)/QI, Steve [GB/GB]; 69 Downs-croft Gardens, Hedge End, Southampton SO30 4RS (GB); AKINSANYA, Karen [GB/GB]; 38 Macnaghten Road, Bitterne Park, Southampton SO18 1GI (GB); HAYWARD, Amanda [GB/GB]; 15 Chesterton Hall Crescent, Cambridge CB4 1AW (GB). (74) Agent: GEERING, Keith, Edwin; Reddie & Grose, 16 Theobalds Road, London WC1X 8PL (GB).	(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	

(54) Title: CONTROLLED RELEASE FORMULATION COMPRISING GNRH-II

(57) Abstract

A pharmaceutical formulation for the controlled release of a therapeutic peptide or a salt thereof, which peptide has the sequence pyroGlu-His-Trp-Ser-Xaa¹-Gly-Xaa²-Xaa³-Pro-Gly-NH₂ wherein Xaa¹ is His or Tyr, Xaa² is Trp or Leu, and Xaa³ is Tyr or Arg, provided that when Xaa¹ is Tyr and Xaa² is Leu, then Xaa³ is not Arg, and which formulation further comprises a pharmaceutically acceptable biodegradable polymer. The formulation can be used for treating bone and prostate disorders.